Results 101 to 110 of about 536 (130)

All-Oral Daclatasvir Plus Asunaprevir for Hepatitis C Virus Genotype 1b: A Multinational, Phase 3, Multicohort Study

Lancet, The, 2014
International audienceBackgroundAn unmet need exists for interferon-free and ribavirin-free treatments for chronic hepatitis C virus (HCV) infection. In this study, we assessed all-oral therapy with daclatasvir (NS5A replication complex inhibitor) plus ...
Cheng-Yuan Peng, Stanislas Pol, Jia H Kao   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Asunaprevir/daclatasvir

Reactions Weekly, 2018
  +12 more sources

Asunaprevir/daclatasvir

Reactions Weekly, 2017
  +11 more sources

Asunaprevir for hepatitis C: a safety evaluation

Expert Opinion on Drug Safety, 2015
The introduction of direct-acting antiviral (DAA) agents has revolutionized the treatment of hepatitis C virus (HCV) chronic infection. Non-structural 3 protease inhibitors are currently the most numerous class of DAAs on the market.This review mainly focuses on the tolerability and safety profile of asunaprevir (ASV)-containing DAA regimens.
GENTILE, Ivan, ZAPPULO, EMANUELA, BUONOMO, ANTONIO RICCARDO, SCOTTO, RICCARDO, BORGIA, GUGLIELMO   +4 more
openaire   +3 more sources

Asunaprevir/daclatasvir

Reactions Weekly, 2015
  +4 more sources

Daclatasvir + Asunaprevir: First Global Approval

Drugs, 2014
The combination of daclatasvir + asunaprevir [Daklinza(®) + Sunvepra(®) (Japan)], two direct-acting antiviral agents, has been developed by Bristol-Myers Squibb for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1 infections, including those with compensated cirrhosis.
openaire   +2 more sources

Asunaprevir/daclatasvir

Reactions Weekly, 2020
openaire   +1 more source

Asunaprevir/daclatasvir

Reactions Weekly, 2019
openaire   +2 more sources

Asunaprevir/daclatasvir

Reactions Weekly, 2022
openaire   +2 more sources

Asunaprevir

Drugs of the Future, 2012
openaire   +1 more source